Advocacy Actions
European Chamber Co-organises EU-China Biopharmaceutical Innovation and Development Roundtable
On 24th November 2022, the EU-China Biopharmaceutical Innovation and Development Roundtable took place using a hybrid format connecting Beijing and Brussels.
The roundtable, co-organised by the European Chamber and the China Society for Drug Regulation (CSDR), with the support from the European Federation of Pharmaceutical Industries and Associations (EFPIA), enabled an open dialogue on pro-innovation regulatory policies between representatives from the European pharmaceutical industry and the National Medical Products Administration (NMPA).
European Chamber Attended CCPIT 2022 Third-quarter Roundtable with Foreign Businesses
On 9th September, European Chamber attended the quarterly online roundtable with foreign chambers and enterprises for the third quarter of 2022, hosted by the Department of Development Research of the China Council for the Promotion of International Trade (CCPIT).
European Chamber Attended CCPIT 2022 First Quarter Online Seminar with FIEs
On 25th March, the European Chamber attended the 2022 First Quarter Online Seminar on Business Environment for Foreign-invested Enterprises in China, organized by the research department of the China Council for the Promotion of International Trade (CCPIT).
Comments to NPC on Anti-Unfair Competition Law (Second Draft for Review)
On September 22, 2017, the European Chamber submitted feedback received from members regarding the call for comments on the second review draft of revision on Anti-Unfair Competition Law issued by the National People’s Congress (NPC).
Read moreLetter to Medical Insurance Department of MOHRSS on Drug Renaming in NRDL
Letter to Medical Insurance Department of MOHRSS on Drug Renaming in NRDL
Read moreComments on CFDA's Announcement 52, 53, 54, 55 on Encouraging Innovation in Pharmaceutical and Medical Devices
European Chamber Pharmaceutical Working Group submitted comments on CFDA's Announcement No. 52, 53, 54, 55 on encouraging innovation in pharmaceutical and medical device.
Read moreComments on MEP's Administrative Regulations on Access to and Benefits Sharing on Biological Genetic Resources (Draft for Comments)
European Chamber Comments on MEP's Administrative Regulations on Access to and Benefits Sharing on Biological Genetic Resources (Draft for Comments)
Read moreComments on Anti-unfair Competition Law (Draft Revision)
The European Chamber submitted consolidated comments from member companies to the National People's Congress on Anti-unfair Competition Law (Draft Revision).
Read moreSpeech at the 2017 International Pharmaceutical Innovation Forum in Nanjing
European Chamber Secretary General Mr. Adam Dunnett gave a keynote speech at 2017 International Pharmaceutical Innovation Forum in Nanjing, raising European businesses' recommendations on promoting innovation in China
Read moreLobby Letter to CFDA on Drug Renaming and Impact on Reimbursement
Lobby Letter to CFDA on Drug Renaming and Impact on Reimbursement
Read more